Zevra Therapeutics (ZVRA) News Today

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) shares have risen today as investors respond to positive analyst upgrades, strong clinical data publications, and sustained price momentum in the rare-disease biotech sector.

• Positive Sentiment: Zacks includes ZVRA among “5 Small Drug Stocks to Buy Amid Trump’s New Tariff Threats,” underlining its innovative pipeline position in the medical-drugs industry. 5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
• Positive Sentiment: Publication in Molecular Genetics and Metabolism of 48-month open-label extension data confirms sustained, long-term efficacy and safety of MIPLYFFA® (arimoclomol) in Niemann-Pick disease type C, bolstering the drug’s clinical profile. Zevra Therapeutics Announces Open Label Extension Data
• Positive Sentiment: MarketBeat reports ZVRA stock has hit a new 12-month high, reflecting strong upward momentum and attracting trend-focused investors. Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High
• Positive Sentiment: William Blair sharply raised its Q2 2025 EPS estimate from $0.09 to $2.26, signaling significantly improved near-term profitability expectations. Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst
• Positive Sentiment: Cantor Fitzgerald lifted its FY2025 EPS forecast to $1.58 (from –$0.17) and reiterated an Overweight rating with a $29 price target, reinforcing bullish expectations for the year.
• Positive Sentiment: Wall Street analysts’ consensus price target implies an 86.6% upside for ZVRA, highlighting continued bullish sentiment on the stock’s long-term growth potential. Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA)
• Positive Sentiment: Trend-focused investors spot ZVRA as a strong short-term pick based on recent price strength and solid fundamentals. Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
• Positive Sentiment: MarketBeat notes a unanimous “Buy” consensus from nine covering brokerages, underlining strong institutional backing. Zevra Therapeutics, Inc. Receives Consensus Rating of “Buy”